iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 3,089 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 3,089 shares of iRadimed stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $84.54, for a total value of $261,144.06. Following the sale, the chief executive officer owned 2,184,411 shares in the company, valued at $184,670,105.94. This represents a 0.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Up 0.6%

Shares of IRMD stock opened at $85.27 on Thursday. The business’s fifty day moving average is $94.40 and its 200 day moving average is $94.67. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of 46.60 and a beta of 0.90. iRadimed Corporation has a twelve month low of $50.88 and a twelve month high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities research analysts expect that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Analyst Ratings Changes

A number of research firms recently weighed in on IRMD. Roth Mkm reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. Weiss Ratings raised iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 6th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Lake Street Capital reiterated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $120.00.

Institutional Trading of iRadimed

Institutional investors have recently made changes to their positions in the stock. CWM LLC grew its stake in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares during the period. Quarry LP purchased a new stake in iRadimed in the third quarter worth approximately $40,000. Farther Finance Advisors LLC boosted its holdings in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares during the last quarter. Tower Research Capital LLC TRC grew its position in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. Finally, State of Alaska Department of Revenue purchased a new stake in iRadimed during the 3rd quarter valued at $47,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.